Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab

Peiyu Xing; Bo Meng; Xiaojia Hu; Wei Qu; Shaowei Wang

doi:10.2147/OPTH.S431145

Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab

Clin Ophthalmol. 2023 Nov 17:17:3491-3497. doi: 10.2147/OPTH.S431145. eCollection 2023.

Authors

Peiyu Xing^#¹, Bo Meng^#², Xiaojia Hu¹, Wei Qu², Shaowei Wang²

Affiliations

¹ Department of Ophthalmology, China Medical University the Fourth People's Hospital of Shenyang, Shenyang, People's Republic of China.
² Department of Ophthalmology, the 2nd Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.

^# Contributed equally.

Abstract

Objective: To assess the functional and anatomical effects of transitioning to conbercept intravitreal injection (IVC) treatment in patients with diabetic macular edema (DME) who had inadequate responses to prior anti-vascular endothelial growth factor (anti-VEGF) injections.

Methods: We retrospectively included eyes with persistent DME after at least 3 injections of intravitreal ranibizumab (IVR). The analysis included the assessment of best corrected visual acuity (BCVA) and central macular thickness (CMT) during 6 months after the switch.

Results: A total of 30 patients (30 eyes) were included. CMT dropped sharply from 437.8±40.67μm at baseline to 363.59±45.09,312.52 ± 39.15, 278.51 ± 37.92, and 292.59 ± 38.09 after 1, 2, 3 and 6 months of IVC, respectively (p <0.001). BCVA in log MAR units was significantly improved from 0.73±0.15 at baseline to 0.50±0.09,0.46±0.72, 0.40±0.06 and 0.48±0.04 after 1, 2, 3 and 6 months, respectively (p <0.001).

Conclusion: Switching to Conbercept effectively improved visual and anatomical structure in DME patients who had not responded satisfactorily to previous anti-VEGF injections.

Keywords: BCVA; CMT; DME; anti-VEGF; anti-vascular endothelial growth factor; best corrected visual acuity; central macular thickness; diabetic macular edema.